🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Please join me in congratulating and welcoming Lukas Delasos new member of Cleveland Clinic Thoracic Oncology Program and member of oncology team at South Pointe Cleveland Clinic MD Nathan A. Pennell MD, PhD, FASCO CCF Hematology Oncology Fellows Cleveland Clinic IM !!

Jame Abraham, MD, FACP Lukas Delasos Cleveland Clinic Cleveland Clinic MD Nathan A. Pennell MD, PhD, FASCO CCF Hematology Oncology Fellows Cleveland Clinic IM We would like to inform you that your post has been successfully published on @Oncodaily. Thank you for sharing! oncodaily.com/blog/99341.html

We are excited to welcome an outstanding group young doctors - as freshly minted Hematology and Medical Oncology Fellows to Cleveland Clinic⁩ ⁦Cleveland Clinic MD⁩ ⁦Cleveland Clinic IM⁩ ⁦CCF Hematology Oncology Fellows⁩ !!

Publication alert 📢 We use "#multiomics machine learning to study host-#microbiome interactions in early-onset vs average-onset colorectal #cancer" Alok Khorana, MD Suneel Kamath MD Naseer sangwan Cleveland Clinic MD Springer Nature npj Journals nature.com/articles/s4169…

🚨🚨 Folks involved with thoracic oncology - please take this IASLC survey, I'm part of the educational committee, and this will help us figure out what educational content to focus on. ❤️

Overview of outcomes with 1L osimertinib JTO & JTO CRR. At progression, continuation of osimertinib associated with shorter survival compared to those who discontinued (!), even after multivariate analysis and even among those who began chemotherapy. jtocrr.org/article/S2666-…

.@asco board member and chair of ASCO AI Task Force Dr. Patt discusses newly released ASCO principles for responsible use of AI in oncology. healio.com/news/hematolog…

#WCLC24 Presidential I Ph III HARMONI-2 ivonescimab v pembro in PDL>1% NSCLC: - 398pts - PFS HR 0.51 (11.1 v 5.82 mPFS) - benefit across histology & PDL1 🌟 Impressive data overall ❓Is this a step forward for PDL1 1-49% grp? 80% males enrolled, data needed in women IASLC

With the goal of addressing a key clinical question, which pts w lung cancer may benefit from adjuvant immunotherapy after neoadjuvant, today at #WCLC2024 we presented results of an exploratory individual pt level analysis of the #CM77T & #CM816 trials 1/

Thank you IASLC for the opportunity to present our research on radiomic biomarkers to predict response to ICI rechallenge for recurrent NSCLC as an oral abstract at #WCLC24!! Very proud of our team's work in this space Anant Madabhushi Nathan A. Pennell MD, PhD, FASCO James Stevenson Maedeh Zokaei Nikoo

I am pleased to share that I am running for the Board of Directors in the ASCO Election. Learn more about me and the 12 other remarkable candidates at asco.org/election, and then make your voice heard!

😊 Join us!

Congratulations to our incoming fellows!

Phase II TROPiCS-03 study of sacituzumab govitecan (TROP2 ADC) in previously treated #SCLC JTO & JTO CRR. RR 42% (35% in platinum resistant, 47.8% in platinum sensitive), DOR 4.7m, PFS 4.4m, OS 13.6m. G3 AEs included neutropenia in 44%, diarrhea in 9%. jto.org/article/S1556-…

Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials | American Society of Clinical Oncology Educational Book ascopubs.org/doi/full/10.12… #ASCO25

With an OS HR identical to KN 671 despite only 3 pre-op cycles, do we really need the adjuvant portion of perioperative treatment? Maybe if it works it just works and you don't need more, from a value perspective the lion's share seems to be in the neoadj tx. Really need a better

🚨 New paper in npj Journals Precision Oncology! We show that radiomics + pathomics improves prediction of recurrence in early NSCLC, ICI response in advanced NSCLC, & chemo response in SCLC. 📌 A step forward in #AI precision oncology for lung cancer. 🔗 rdcu.be/eppuU

🎸 Cutting-edge science takes the stage! Join Lukas Delasos of Cleveland Clinic at the OncLive Lung Cancer State of the Science Summit on June 24 at the House of Blues Cleveland. 🔗 Save your seat: hubs.li/Q03qd2gQ0 #OncLiveSOSS #LungCancer

🌟 Big breakthroughs in lung cancer care are happening—don’t miss your chance to catch it live in Cleveland! Join Lukas Delasos of Cleveland Clinic at the OncLive State of the Science Summit on June 24 at the House of Blues Cleveland. Register Now➡️hubs.li/Q03qd2Cz0